Your scientific partner for drug and in-vitro diagnostic development.
Pacific Biomarkers is a biomarker testing services provider, supporting pharmaceutical, biotech and in-vitro diagnostic (IVD) manufacturing companies through preclinical and Phase I-IV studies of drug and IVD development.
Pacific Biomarkers has an established reputation for expertise, flexibility, protocol consultation, and outstanding client services that has propelled the company to a prominent position in the rapidly growing pharmaceutical outsourcing industry. With over 300 fully CLIA validated assays and an extensive network of scientific, regulatory, and technology expertise, Pacific Biomarkers is the service provider of choice for many leading international drug manufacturers in the race to bring products to market as quickly and cost effectively as possible.
Pacific Biomarkers provides accurate, reliable analyses, and responsive service to sponsors and investigative sites. Pacific Biomarkers collaborates with sponsors to develop, validate, improve analytical methods, and provide technical consultation for protocol design. Our services are customized on a project specific basis which allows Pacific Biomarkers to be more flexible to meet the needs of our clients.
Pacific Biomarkers is a CAP accredited and CLIA certified laboratory. Pacific Biomarkers also provides GLP compliant biomarker laboratory services.
Originally named Pacific Biometrics, Inc., Pacific Biomarkers was founded in 1989 as a spin-off from the University of Washington Lipid Research Center, Dept. of Medicine. Founders Dr. Elizabeth Leary and Russ Warnick had a vision for global standardization of lipid testing. When the CDC initiated the Cholesterol Reference Method Laboratory Network (CRMLN), Pacific Biomarkers became a member of this network: three labs in the U.S. and 11 globally. For 20 years, Pacific Biomarkers provided lipid reference and standardization services for in-vitro diagnostic manufacturers and clinical laboratories.
During this time, Pacific Biomarkers began consulting with pharmaceutical companies to support drug development. This clinical trial support has now become a core business of the company. Traditionally, our therapeutic focus has been cardiovascular and musculoskeletal diseases, diabetes, obesity, metabolic syndrome, and inflammation. Today, we have evolved to meet the needs of our customers, providing biomarker support across a wide range of therapeutic areas.
In 2007, Pacific Biomarkers expanded its capabilities into immunogenicity testing, cell based assay services, and novel biomarker development. Shortly after in 2009, Pacific Biomarkers officially changed its name to Pacific Biomarkers to better reflect our business. In an effort to expand our clinical trial testing to Asia, Pacific Biomarkers partnered with Syngene International Ltd. and Wuxi AppTech in 2011 and 2014, respectively. Through these strategic collaborations, we can offer our 300+ CLIA validated biomarkers across diverse therapeutic areas in Asia with added capabilities within immunogenicity and cell based functional assays in a cost effective business model.
More recently in 2015, we introduced the Pacific Biomarkers Mobile App; an interactive platform that provides access to innovative tools such as the BIOMARKER NAVIGATOR and allows you to create biomarker information reports instantly from our broad biomarker testing menu.
Ronald Helm, JD
Chief Executive Officer
Ronald Helm became the CEO and principal owner of Pacific Biomarkers in September of 2011 in the transition that made Pacific Biomarkers a privately held company. Mr. Helm had become chairman and CEO of Pacific Biometrics, Inc. in August of 2002. In 2009, the name of the company was changed to Pacific Biomarkers.
Mr. Helm is a co-founder of Saigene Corporation and served as Chairman and CEO until July of 2002. Prior to forming Saigene in 1996, Mr. Helm was Chairman of the Board and Chief Executive Officer of a biotech company in Southern California and has held senior management positions in the industry since 1992.
For nearly nine years, Mr. Helm served as the Associate Dean for Development and Professor of Law at Pepperdine University School of Law in Malibu, California and following that, was the Senior Vice-President and General Counsel of ComputerLand Corporation, which became Vanstar Corporation (a NYSE company). Mr. Helm went on to found the California law firm of Helm Purcell and Wakeman, where he remained “of counsel” until 2000. He also served as a Managing Director of ComputerLand Europe, an independent private company with 130 retail outlets in 15 countries. Mr. Helm is a member of the Bar of California State and is admitted to practice before the United States Supreme Court.
Amar A. Sethi, MD, PhD
President and Chief Scientific Officer
Dr. Amar Sethi joined Pacific Biomarkers in 2009 and serves as its President and Chief Scientific Officer (CSO). Prior to being appointed CSO in 2012, Dr. Sethi served as the Company’s Vice President of Research and Development. In his current position, Dr. Sethi provides leadership and strategic direction for the Company. He is responsible for evaluating and setting the Company’s scientific priorities, coordinating administrative structures and developing business relationships within the scientific and client communities. Dr. Sethi earned an M.D. in Clinical Biochemistry and a Ph.D. in Genetics of Cardiovascular Diseases from the University of Copenhagen, School of Medicine, in 1996 and 2003, respectively. Dr. Sethi is board certified in Chemical Pathology by the National Board of Health, Denmark. He has broad experience in clinical diagnostics laboratories in both the U.S. and Europe including molecular diagnostic screening, overseeing chemistry, hematology, coagulation and immunology. Dr. Sethi has extensive research experience in basic and clinical research of atherosclerotic diseases. He is the current Chair of the Lipids and Vascular Disease Division of the American Association of Clinical Chemistry. He has served as an ad hoc reviewer for multiple international peer-reviewed journals, presented extensively at international scientific meetings, and has published widely in peer-reviewed journals and book.
John P. Jensen
Vice President of Finance and Business Systems
John Jensen joined Pacific Biomarkers in 2005 as Controller and now holds the position of Vice President. As Vice President of Finance, Mr. Jensen is in charge of strategic financial planning, budget preparation and responsible for of all financial reports that summarize the organization’s financial position. He ensures that sound financial practices are adhered to throughout the organization. Mr. Jensen manages the accounting department, human resources, banking, cash management, risk management, taxation and the annual audit. On the Business Systems side his duties include evaluation of new technologies for proper enterprise return on invested capital, providing financial resources for business development with pricing collaboration on client proposals and partnerships, consultation on technology purchases including their implementation and facility management.
Mr. Jensen has a strong background in financial management with over twenty five years of experience in a variety of sectors including manufacturing, professional service, and retail medical supplies. He has broadened his skill sets beyond the financial role and held senior management positions including Director of Operations for Seattle Lab and Vice President of Operations for Utility Inc.
Mr. Jensen received his Bachelors of Arts in Business Administration with a Minor in Mathematics at Eastern Washington University in Cheney, Washington. He serves as a board member of the NABFO, the Northwest Association of Bioscience Financial Officers group, a local chapter of APFO, the National Association of Bioscience Financial Officers. Mr. Jensen is also a member of the CFO Roundtable group, a local discussion group of small to mid-size public and private Chief Financial Officers. He formerly served the local community as chair of the Planning Policy Commission for the City of Issaquah and as a member of the King County Metro Transit Advisory Committee.
Maribeth Raines, PhD
Vice President of Laboratory Services
Dr. Maribeth Raines joined the Company in 2012 and serves as its Vice President of Laboratory Services. In her current position, Dr. Raines manages the laboratory operations including all technology transfers at Pacific Biomarkers. In her current role, Dr. Raines is responsible for providing scientific leadership and technical support to the Company’s laboratory operations and R&D programs. Dr. Raines is biochemist with a broad-based background in a variety of areas but especially in oncology, inflammation, and virology as well as in biomarker discovery, development and commercialization. Prior to joining Pacific Biomarkers, Dr. Raines served as Director of Scientific Affairs for Quest Diagnostics Clinical Trials, where she helped establish biomarker, anatomic pathology, and flow cytometry testing for drug development. She was also responsible for building strategic alliances in emerging markets, standardizing processes, and harmonizing test results among multiple laboratories for global biomarker deployment. Prior to that position, she served as Director of R&D at both Nichols Institute Diagnostics and BioSource International (now known as Life Technologies). In addition, she has served on the faculty at UCLA School of Medicine in the Radiation Oncology Division. Dr. Raines earned a B.S. degree in Biology from St. Francis University, and a Ph.D. in Biochemistry from Michigan State University.
Tonya K. Aggoune
Vice President of Project Services
Tonya Aggoune is the Vice President of Project Services which includes responsibility for the Project Management, Data Management, and Information Technology Departments of Pacific Biomarkers. She joined the company in 1997 as the Manager of Information Systems, which included the data management and information technology functions. In 2000, she also became responsible for the Project Management Department (then known as Client Services).
Since joining Pacific Biomarkers as the head of Information Systems, Ms. Aggoune has been responsible for information technology (IT), computer operations, and the Laboratory Information Systems database. She is also the principle liaison between Pacific Biomarkers and client Data Management personnel to develop requirements for reporting, data transfer, and other custom database applications for pharmaceutical and diagnostic studies. Pacific Biomarkers recognizes the benefit of a close relationship between project management and data management in a company whose product is information (laboratory data); thus Ms. Aggoune became responsible for heading the Project Management Department in 2000. This team oversees project management of our pharmaceutical and diagnostic/referral studies. The team is responsible for coordinating the laboratory services needed to meet the sponsor’s study requirements and serves as the principle liaison between the sponsor’s project management and Pacific Biomarkers.
Ms. Aggoune has a BA in Biological Sciences and BS in Electrical Engineering. Her background includes extensive experience as a systems engineer in aerospace research and laboratory information systems in the Health Care industry. As an engineer at Boeing Aerospace, she designed and developed prototypes for computer based training systems, paper-less maintenance systems, and command/control/communication systems. She later joined National Health Laboratories (later became LabCorp) as Assistant Manager of Information Systems where she was able to bring together her experience with computer systems/software and her background in biological sciences.
Michael Murphy, PhD
Laboratory Director, BD/Strategic Relations
Michael Murphy originally joined Pacific Biomarkers (formerly Pacific Biometrics, Inc.) in 1997 as Director of Laboratory Services. He served in that role until 1999 before returning to the commercial clinical reference laboratory industry. Dr. Murphy returned to Pacific Biomarkers in 2005 as Senior Vice President, Operations and was later named Chief Operating Officer in 2009. Dr. Murphy managed all aspects of the service business including laboratory operations, client and information services, and quality assurance. Dr. Murphy worked with senior management to execute business development initiatives as well. Currently Dr. Murphy serves as the Laboratory Director/BD Strategic Client Relationships. He provides CAP/CLIA regulatory lab oversight and is very active in fostering strategic relationships with client and vendor partners.
Dr. Murphy brings more than 30 years of laboratory experience to Pacific Biomarkers. He has extensive experience in the management and direction of technical, scientific and operational elements within clinical diagnostic, commercial reference, CRO, global central and research laboratories. Dr. Murphy has served as a principle investigator in research and diagnostic studies. Areas of expertise include: biomarker validation and standardization, quality assurance, laboratory operations, informatics and laboratory automation. Research and clinical areas of interest include diabetes, infectious, cardiovascular, oncology and musculoskeletal disease. Dr. Murphy received his B.S. from Xavier University and Ph.D. from The Ohio State University. He is a Diplomate of the American Board of Clinical Chemistry (DABCC).
Vice President of Business Development
Tim Hynes joined Pacific Biomarkers in 2016 and serves as Vice President of Business Development. In this capacity he is responsible for managing all business development activities, oversees the business development executives as well as all marketing initiatives. Mr. Hynes comes to Pacific Biomarkers with over 25 years in the industry having held positions with global CROs, Central Laboratories and Contract Manufacturing Organizations. He most recently served with PPD Central Laboratories as a senior business development executive. His comfort level extends from the global pharma and biotech client as well as the emerging players so prevalent throughout the industry. He is well published and earned his BS degree from Southampton College, part of Long Island University, in Marine Science.
Candace Adamo, PhD
Senior Scientist, Organ Injury Biomarkers
Dr. Candace Adamo joined Pacific Biomarkers as an Organ Injury Biomarker Scientist in March, 2014 and has now assumed oversight of the Safety Biomarker Program. This program explores the use of novel biomarkers to assess organ injury due to toxic effects of drugs in development or other circumstances such as transplantation, contrast-induced injury, sepsis or trauma. Dr. Adamo is evaluating combinations of the most promising biomarkers to identify acute kidney injury (AKI) and injury to other organs for use in clinical and preclinical safety studies. Her work is currently focused on qualifying markers that are clinically significant with the PSTC and FDA. She also contributes to the development of business strategies and marketing of the Safety Biomarker Program at Pacific Biomarkers. Dr. Adamo earned a Ph.D. from the University of Washington, Pharmacology Department in 2011, where she characterized the cardioprotective effect of sildenafil citrate (Viagra®) on the mdx mouse model of Duchenne muscular dystrophy (DMD) using echocardiographic assessment of cardiac structure and function. She continued her training in vascular biology while completing her post doctorate at Emory University, School of Medicine. Her background includes immunoassays, cell-based assays, advanced microscopy and both protein and gene expression analysis.
Timothy Carlson, PhD, RD, NRCC
Timothy Carlson joined Pacific Biomarkers (then, Pacific Biometrics, Inc.) in 1998 as a Senior Scientist. He was promoted to the position of Laboratory Director in May of 2000 and currently serves as Senior Consultant.
Dr. Carlson has broad training and experience in basic and clinical sciences. He has received grant research awards from the National Institutes of Health, American Blood Systems Research Foundation, American Association of Blood Banks, and the American Heart Association. Dr. Carlson has published more than 75 research papers, chapters, and abstracts in the areas of nutrition, chronic disease, and homeostasis. He is a registered clinical chemist and dietitian, and holds a PhD in Biochemistry.
He has completed his post doctorates in Protein Chemistry and in Clinical Chemistry. He was a Fogherty International Scholar at the University of Lund in Malmö, Sweden. Dr. Carlson served on the American Association for Clinical Chemistry Abstract Review Committee, as the Editor of The Nutrition Forum, on the newsletter of the Nutrition Division of the American Association for Clinical Chemistry Nutrition, and as Secretary for the Lipoproteins and Vascular Disease Division of the American Association for Clinical Chemistry.
Ken Waters, JD
Director of Strategic Planning
Ken Waters became the Director of Strategic Planning for Pacific Biomarkers in September 2002. His primary focus is to assist the Company with corporate and strategic partnering activities.
Mr. Waters has also established his own business and legal consulting practice associating with several well-known firms. His clients have included AT&T, Williams-Sonoma, Commodore International, CMS Enhancements Inc., ComputerLand, Power Up Software, Peerless Systems Corporation, and CelluLand. Mr. Waters has specialized in the computer industry, corporate turnarounds, restructuring, and providing advice in the franchise field. He has had experience in manufacturing, retail, and distribution in companies of varying sizes. He has associated himself in the past with Frank Lynn & Associates in Chicago, and with Grisanti, Gaileff, and Goldreff.
Mr. Waters is the former CEO of ComputerLand Corporation, President of Power-Up Software, and President of Microage Corporation. During his tenure at ComputerLand, the company became the world’s largest retail computer company with over 800 stores worldwide. At the time he was President, Microage Corporation was the largest public company headquartered in Arizona. Mr. Waters has a BA in Political Science/History and is a member of the California Bar Association. He was rated one of the Top 25 most influential executives in the computer industry by the Computer Reseller News for 1987 and 1988.
Director of Laboratory Operations
Dave Swezey became the Director of Laboratory Operations in 2009. In this role, he oversees all of the analytical testing services in the main laboratory at Pacific Biomarkers. His position works closely with both the Science & Technology and Quality Assurance departments. A key component of his responsibilities includes employing engineering principles to improve laboratory processes and procedures at the pre-analytical, analytical, and post-analytical phases of testing. His 15 years of experience in working with laboratory robotics is applied in streamlining complex testing in the Laboratory. He is also responsible for the training program for new Laboratory employees.
Mr. Swezey joined the company in 1997 as the Technical Supervisor in the Laboratory and moved into the position of Quality Assurance Manager in 2000. Mr. Swezey received his Bachelor of Arts degree in Biology from Humboldt State University in Arcata, California. He then earned his license as a Registered Medical Technologist through an internship at Cottage Hospital in Santa Barbara, California in 1979. After his internship he served as Chemistry Supervisor at Medical Group Pathology Laboratory until 1990, when he moved to the Seattle area and served as the Night Laboratory Manager for Laboratory Corporation of America in Kent, Washington until 1997.
Quality Assurance Manager and Safety Officer
Jason Ray became the Quality Assurance Manager for Pacific Biomarkers Inc in 2009 after working in the department and as the Quality Assurance Supervisor for several years. As the Quality Assurance Manager, Mr. Ray leads the Quality Assurance department’s efforts to ensure the company’s quality objectives and regulatory requirements are met, as well as manage the document control system, internal audits, and regulatory and client audits. Additionally, Mr. Ray functions as the Safety Officer for Pacific Biomarkers Inc. and is responsible for ensuring safety compliance, injury investigation, and training.
Mr. Ray’s background includes 16 years of progressive responsibility and leadership roles throughout the industry including medical device, pharmaceutical, and diagnostic companies. Mr. Ray received his Bachelors of Science in Biology at Colorado State University in Fort Collins, Colorado. Prior to joining Pacific Biomarkers in 2003, Mr. Ray developed a strong assay development background starting out as a QC technician at a medical device company, and continued to advanced to a position of Research Associate IV at a molecular diagnostic company where he designed and developed custom assays for clients ranging from the health, veterinary, and environmental fields. Mr. Ray owned and operated a small manufacturing business for 10 years supporting molecular research at university, governmental agencies, and non-profit organizations, and additionally has consulted for the diagnostic industry in the capacity of technical assay development, product development and launch, as well as manufacturing.
Jeff Chamberlain, PhD
Associate Scientist, Business Development
Jeff Chamberlain joined the business development team at Pacific Biomarkers in 2014, bringing with him a background in bioengineering and technology commercialization. He is accountable for advancing and maximizing sales by identifying growth opportunities and applying a technical and scientific sales approach.
Prior to coming to Pacific Biomarkers, Dr. Chamberlain worked for Zwitter Technology, a startup company that was founded to commercialize a polymeric coating technology with applications in many fields including medicine, medical devices, and marine coatings. As the Project Lead and Manager of Business Development, he oversaw a collaborative project with a large pharmaceutical company and was the Principal Investigator on a Phase II SBIR grant. He also represented the company in fundraising efforts and pitches to potential industrial collaborators. Dr. Chamberlain worked as a contractor for Peyvan Systems, an engineering consulting and product development company based in Seattle.
Dr. Chamberlain earned his Ph.D. in Bioengineering at the University of Washington, Seattle, where he leveraged multiple biosensing modalities to study bacterial binding and biomolecular interaction analysis. He also obtained the Technology Entrepreneurship Certificate from the UW Foster School of Business and served as president of the UW Science & Engineering Business Association (SEBA). He is a frequent volunteer in the Seattle life sciences business community, primarily through his involvement with the Washington Biomedical and Biotechnology Association (WBBA).
Elizabeth Teng Leary, PhD, DABCC
Co-founder and Sr. Scientific Advisor
Elizabeth Leary, co-founded Pacific Biometrics, Inc. (Pacific Biomarkers) and Pacific Biometrics Research Foundation (PBRF) in l989. She served as the Vice President of Laboratory Services until the spring of 2000 when she became Chief Scientific Officer. As the Pacific Biomarkers Laboratory’s Chief Science Officer, Dr. Leary lends her expertise within the company and consults actively for the diagnostic and pharmaceutical industries. Her areas of focus are in laboratory support of clinical trials and product research in cardiovascular diseases, osteoporosis, and diabetes.
Dr. Leary served as a director of clinical chemistry and industry consultant for 13 years prior to joining Pacific Biometrics, Inc. Dr. Leary received her degrees in Biochemistry from University of California at Berkeley and Purdue University. She is a diplomate of the American Board of Clinical Chemistry. Dr. Leary is the director of the CDC Cholesterol Reference Network Laboratory at PBRF (one of ten in the world). She is past chair of the Pacific Northwest chapter of American Association for Clinical Chemistry (AACC) and the Lipids and Vascular Diseases Division of AACC, and past president of the North American Chinese Clinical Chemists Association. She has published over 80 articles in peer-reviewed journals and books, and is a recipient of several grants and awards.
Pacific Biomarkers currently has six Advisory Board members who bring combined experience in academia, pharmacology and central reference labs.
Ronald L. Gingerich, Ph.D., President, Conturix Research, Inc.; formerly founder and CEO of LINCO Research, Inc. Dr. Gingerich earned a PhD degree from Indiana University in 1975 and completed postdoctoral training at Washington University School of Medicine where he served on the faculty for 20 years. During his tenure at Washington University he held positions of Associate Research Professor and Director of the Radioimmunoassay Facility. Dr. Gingerich founded LINCO Research, Inc in 1978, a company focused on providing analytical research tools to the academic, biotech and pharmaceutical diabetes and obesity markets. LINCO Research was an early adopter of the Luminex Multiplexing technology. He later founded LINCO Diagnostic Services, Inc to provide GLP biomarker analytical services support for preclinical and clinical drug development trials for major biotech and pharmaceutical companies. He served as CEO and Chief Scientific Officer for both companies until their acquisition by Millipore Corporation (now part of EMD Merck) in 2006. Dr. Gingerich is an active member of professional societies in the life-sciences industry such as the American Diabetes Association, American Association of Lab Animal Science, American Association for Clinical Chemistry and the American Association of Pharmaceutical Scientists. Dr. Gingerich has authored over 100 publications and holds 2 patents.
Jack C. Bloom, V.M.D., Ph.D. holds a B.S. degree in biology from the University of Pittsburgh and doctorates in veterinary medicine and experimental hematology from the University of Pennsylvania. He completed his postdoctoral training at Jefferson Medical College in hematology/oncology and served on the Faculty of the University of Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Laboratories as Associate Director of Pathology. He later joined Lilly Research Laboratories as Head, Clinical Pathology, in the Toxicology Division, and subsequently moved to the Medical Division, where he established the departments of Clinical Laboratory Medicine, Experimental Medicine and Clinical Diagnostic Services. As Executive Director and Distinguished Medical Fellow, Diagnostic and Experimental Medicine, he was responsible for routine laboratory, ECG, imaging and specimen banking support for global clinical development; and novel clinical biomarker discovery, validation and application in the Division of Translational Medicine and Pharmacogenomics. Upon his retirement from Lilly in 2009 he established Bloom Consulting Services, LLC and was appointed Special Consultant, Office of the Center Director, FDA. Dr. Bloom serves on several Scientific Advisory Committees for pharmaceutical, diagnostic and pharmaceutical services companies and holds adjunct academic appointments at the University of Pennsylvania and Purdue University.
Gordon F. Kapke, Ph.D., DABCC, FACB has more than 40 years of clinical lab experience. Dr. Kapke has generated research data in the university setting, community hospital setting, and the global clinical laboratory setting. He has been a key figure in implementing regulated laboratories in Europe, Africa, Australia, and Asia. With 20 years of experience supporting clinical trials, Dr. Kapke’s most recent interest is in Bayesian analysis of clinical trial biomarker data.
Jay Heinecke, M.D. is Professor, Department of Medicine, Karasinski Charin Metabloic Research, University of Washington. The major focus of research in the Heinecke laboratory is to understand the role of HDL and macrophages in the pathogenesis of atherosclerosis, diabetes and other inflammatory diseases. Current studies center on the investigation of the pathways that promote cholesterol efflux from macrophages, which is of central importance in the cardioprotective effects of. The Heinecke research group also has a major interest in translational studies to determine if altered HDL protein composition, macrophage sterol efflux, and inhibition of macrophage inflammation associate with CAD and diabetic status.
Deborah Phippard, Ph.D.
Built in 2012 from a cold shell, we have completely customized over 21,000 sq. ft. of expandable space including a CAP/CLIA certified laboratory.
In an effort to expand clinical trial testing to Asia, Pacific Biomarkers partnered with Syngene International Ltd. and Wuxi AppTech in 2011 and 2014, respectively.
Syngene International Ltd., a Biocon company, is a leading custom research and manufacturing organization supporting drug development from lead generation to clinical supplies. Syngene offers bioanalytical services (for small molecules and biologics) in addition to specialty tests such as immunogenicity screening assays, neutralizing antibody assays, cell based assays and ligand binding characterization assays. Clinical laboratory services provided by Syngene range from moderate to high complexity assays such as customized flow cytometry and immunohistochemistry assays.The Pacific Biomarkers-Syngene partnership combines biomarker support for clinical trial research of the former with development capabilities of ligandbinding assays of the latter in a cost-effective business model situated in India. Both laboratories are CAP and GLP certified with strong emphasis on regulatory compliance and quality assurance providing reliable analytical data that stands up to the most rigorous regulatory and scientific scrutiny.
WuXi AppTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The Pacific Biomarkers-WuXi partnership allows us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China.
Through our strategic collaborations, Pacific Biomarkers can offer its 300+ CLIA validated biomarkers across diverse therapeutic areas in Asia with added capabilities within immunogenicity and cell based functional assays in a cost-effective business model.